LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Aandelen Lijst・Pulmatrix Inc

Pulmatrix Inc

Gesloten

4.19 7.16

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.89

Max

4.32

Belangrijke statistieken
By Trading Economics
Inkomsten	672K -877K
EPS	-0.24
Winstmarge	-60,266.667
Werknemers	2
EBITDA	671K -877K

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-3.3M 15M
Vorige openingsprijs	-2.97
Vorige sluitingsprijs	4.19

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 dec 2025, 22:13 UTC

Winsten

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dec 2025, 21:40 UTC

Winsten

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dec 2025, 18:51 UTC

Acquisities, Fusies, Overnames

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dec 2025, 16:57 UTC

Belangrijke Marktbewegers

Clear Secure Rises on Medicare Identity Verification Contract

9 dec 2025, 23:46 UTC

Marktinformatie

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dec 2025, 23:46 UTC

Acquisities, Fusies, Overnames

Legend Holdings Stake in Lenovo Now at 32.34%

9 dec 2025, 23:45 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dec 2025, 23:44 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dec 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dec 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dec 2025, 23:35 UTC

Marktinformatie

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dec 2025, 22:42 UTC

Winsten

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dec 2025, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

9 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 dec 2025, 21:48 UTC

Marktinformatie

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dec 2025, 20:28 UTC

Marktinformatie

Oil Futures Decline for Second Straight Session -- Market Talk

9 dec 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dec 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Teck Reports Voting Results From Special Meeting of Hldrs

9 dec 2025, 20:26 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dec 2025, 20:21 UTC

Marktinformatie

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dec 2025, 19:52 UTC

Winsten

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dec 2025, 19:17 UTC

Winsten

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 dec 2025, 17:11 UTC

Winsten

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pulmatrix Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.